Biotron Ltd (BIT) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.322x

Based on the latest financial reports, Biotron Ltd (BIT) has a cash flow conversion efficiency ratio of -0.322x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-868.42K ≈ $-614.46K USD) by net assets (AU$2.70 Million ≈ $1.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Biotron Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)

This chart illustrates how Biotron Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Biotron Ltd for a breakdown of total debt and financial obligations.

Biotron Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biotron Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
NCC Group plc
LSE:NCC
0.092x
Star Fashion Culture Holdings Limited
NASDAQ:STFS
-0.479x
Zenvia Inc
NASDAQ:ZENV
-0.034x
Chenghe Acquisition II Co.
NYSE MKT:CHEB
-0.002x
Binect AG
XETRA:MA10
0.012x
Polar Power Inc
NASDAQ:POLA
0.141x
Global Sukses Solusi Tbk PT
JK:RUNS
-0.002x
REGENCY SILVER CORP.
F:ZJ9
N/A

Annual Cash Flow Conversion Efficiency for Biotron Ltd (2001–2025)

The table below shows the annual cash flow conversion efficiency of Biotron Ltd from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see BIT company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$551.89K
≈ $390.50K
AU$-565.80K
≈ $-400.34K
-1.025x -107.01%
2024-06-30 AU$-244.03K
≈ $-172.67K
AU$-3.57 Million
≈ $-2.52 Million
14.623x +1510.16%
2023-06-30 AU$3.17 Million
≈ $2.24 Million
AU$-3.29 Million
≈ $-2.33 Million
-1.037x +53.49%
2022-06-30 AU$1.09 Million
≈ $773.01K
AU$-2.44 Million
≈ $-1.72 Million
-2.230x -152.78%
2021-06-30 AU$3.86 Million
≈ $2.73 Million
AU$-3.41 Million
≈ $-2.41 Million
-0.882x -99.59%
2020-06-30 AU$6.97 Million
≈ $4.93 Million
AU$-3.08 Million
≈ $-2.18 Million
-0.442x -60.48%
2019-06-30 AU$5.44 Million
≈ $3.85 Million
AU$-1.50 Million
≈ $-1.06 Million
-0.275x +80.84%
2018-06-30 AU$1.28 Million
≈ $906.75K
AU$-1.84 Million
≈ $-1.30 Million
-1.437x +26.95%
2017-06-30 AU$1.44 Million
≈ $1.02 Million
AU$-2.83 Million
≈ $-2.00 Million
-1.968x -100.34%
2016-06-30 AU$3.14 Million
≈ $2.22 Million
AU$-3.08 Million
≈ $-2.18 Million
-0.982x -49.61%
2015-06-30 AU$4.14 Million
≈ $2.93 Million
AU$-2.72 Million
≈ $-1.92 Million
-0.656x +69.35%
2014-06-30 AU$1.39 Million
≈ $983.02K
AU$-2.98 Million
≈ $-2.11 Million
-2.142x -210.15%
2013-06-30 AU$4.48 Million
≈ $3.17 Million
AU$-3.09 Million
≈ $-2.19 Million
-0.691x -149.63%
2012-06-30 AU$8.27 Million
≈ $5.85 Million
AU$-2.29 Million
≈ $-1.62 Million
-0.277x +66.27%
2011-06-30 AU$2.40 Million
≈ $1.70 Million
AU$-1.97 Million
≈ $-1.39 Million
-0.820x +24.19%
2010-06-30 AU$1.72 Million
≈ $1.22 Million
AU$-1.86 Million
≈ $-1.31 Million
-1.082x +51.88%
2009-06-30 AU$841.51K
≈ $595.42K
AU$-1.89 Million
≈ $-1.34 Million
-2.249x -155.50%
2008-06-30 AU$1.84 Million
≈ $1.30 Million
AU$-1.62 Million
≈ $-1.15 Million
-0.880x +67.26%
2007-06-30 AU$1.36 Million
≈ $959.47K
AU$-3.65 Million
≈ $-2.58 Million
-2.688x -576.13%
2006-06-30 AU$4.50 Million
≈ $3.18 Million
AU$-1.79 Million
≈ $-1.26 Million
-0.398x +47.04%
2005-06-30 AU$2.28 Million
≈ $1.61 Million
AU$-1.71 Million
≈ $-1.21 Million
-0.751x +14.84%
2004-06-30 AU$2.96 Million
≈ $2.09 Million
AU$-2.61 Million
≈ $-1.84 Million
-0.882x -344.86%
2002-06-30 AU$8.49 Million
≈ $6.01 Million
AU$-1.68 Million
≈ $-1.19 Million
-0.198x -52.42%
2001-06-30 AU$10.08 Million
≈ $7.13 Million
AU$-1.31 Million
≈ $-927.34K
-0.130x --

About Biotron Ltd

AU:BIT Australia Biotechnology
Market Cap
$4.78 Million
AU$6.75 Million AUD
Market Cap Rank
#28438 Global
#1579 in Australia
Share Price
AU$0.00
Change (1 day)
+25.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.30
About

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.